Pemafibrate

Chemical formula: C₂₈H₃₀N₂O₆  Molecular mass: 490.21 g/mol  PubChem compound: 11526038

Therapeutic indications

Pemafibrate is indicated for:

Dyslipidemia characterised by high TG ≥150 mg/dL

Population group: only adults (18 years old or older)

Pemafibrate is indicated as adjunctive therapy to diet or other nonpharmacological treatment (e.g. exercise) to reduce TG and to increase HDL-C in patients with dyslipidemia characterised by high TG ≥150 mg/dL, particularly when there is evidence of associated risk such as hypertension and smoking.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Pemafibrate is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Moderate hepatic disorder, severe hepatic disorder, biliary obstruction

at least one of
Hepatic failure stage III
Hepatic failure stage IV
Obstruction of biliary tree

Cholelithiasis

Biliary calculus

Ciclosporine

Ciclosporin

Rifampicin

Rifampicin

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Medication Package Insert (MPI) 2022: PARMODIA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈